Sodium acetate

A.forall Announces Launch of a Generic Version of Sodium Acetate Injection 4 mEq/mL

Retrieved on: 
Tuesday, January 9, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Hospitals, Sodium acetate, CGT, Patient, Sodium, Hyponatremia, Food, Sanda, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240109663266/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240109663266/en/
    Sodium Acetate Injection 4 mEq/mL is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake.
  • Milla Pharmaceuticals was previously granted a Competitive Generic Therapy (CGT) designation for its generic drug product, Sodium Acetate Injection, 2 mEq/mL, by the FDA in 2021, which has been commercialized since July 2021.
  • The Sodium Acetate Injection 4 mEq/mL has been consistently listed on the FDA Drug Shortages List for the last several years.
  • “With this sANDA, an alternative concentration of the Sodium Acetate Injection we launched two years ago, we again substantially increase the availability of a life-saving drug that U.S. patients would otherwise be lacking.

Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Yet Another “First Cycle” FDA Approval for an Abbreviated New Drug Application (ANDA), Dexmedetomidine Hydrochloride Injection

Retrieved on: 
Friday, June 9, 2023
FDA, Hospitals, Biotechnology, Managed Care, Health, Pharmaceutical, General Health, Retail, Supply Chain Management, Paragraph, Multimedia, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Hospital, Sodium acetate, Acquisition, Patient, File, Dexmedetomidine, ANDA, Summer, Generic drug, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20230609005336/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230609005336/en/
    Dexmedetomidine Hydrochloride Injection is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting.
  • Dexmedetomidine Hydrochloride Injection 4mcg/ml in 50mL and 100mL is currently on FDA’s Drug Shortages list.
  • This latest approval of Dexmedetomidine Hydrochloride Injection will help reduce the recent supply issues for the product experienced in the U.S.
  • This new milestone also marks the approval of our second Paragraph IV Filing and the 5th ANDA approval for the Alter Pharma Group.

Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Launch of a Generic Version of Magnesium Sulfate in Water for Injection, in Non-PVC, Single-Patient Use Containers by Their Partner Athenex Pharmaceutical Division (APD)

Retrieved on: 
Monday, March 20, 2023
Supply Chain Management, Retail, Health, FDA, General Health, Pharmaceutical, Biotechnology, Seizure, Central nervous system, Eclampsia, Paracetamol, Convulsion, Water, Magnesium sulfate, Multimedia, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Hospital, Sodium acetate, Acquisition, Patient, APD, Plasma protein binding, Injection, Pre-eclampsia, Infant, ANDA, ASHP, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Safety, Pharmaceutical industry, EU

View the full release here: https://www.businesswire.com/news/home/20230320005186/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230320005186/en/
    Alter Pharma #MakingAffordableMedicinesAvailableToAll Every day we ensure equal access to medicines and continuity of treatment for patients.
  • (Graphic: Business Wire)
    Magnesium Sulfate Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia.
  • This latest launch of Magnesium Sulfate Injection will help reduce the recent supply issues for the product experienced in the U.S.
  • This achievement marks the second ANDA commercialization for Milla Pharmaceuticals Inc. and the third for an Alter Pharma Group product in the U.S. market.

Global Sodium Acetate Trihydrate & Sodium Acetate Anhydrous Market Report to 2028 - by Product Type, End-use and Region - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 15, 2022
Chemicals, Plastics, Other Manufacturing, Manufacturing, CAGR, Industry, US, Polymerization, Metal, Growth, PEG, Marketing, Hydrate, Sodium acetate, Color, Plastic, SLS, Propylene glycol, PEO, Plasticizer, Acetate, Commodity chemicals, Tons

The "Sodium Acetate Trihydrate & Sodium Acetate Anhydrous Market - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sodium Acetate Trihydrate & Sodium Acetate Anhydrous Market - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • Sodium Acetate is one of the most common plasticizers used in the United States and around the world.
  • Sodium Acetate Trihydrate & Sodium Acetate Anhydrous are commonly found together.
  • Key features of the study:
    This report provides in-depth analysis of the sodium acetate trihydrate & sodium acetate anhydrous market, and provides market size (US$ Thousand and Tons) and compound annual growth rate (CAGR%) for the forecast period (2021-2028), considering 2020 as the base year
    This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
    It profiles key players in the global sodium acetate trihydrate & sodium acetate anhydrous market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
    Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, Product type up-gradation, market expansion, and marketing tactics
    The global sodium acetate trihydrate & sodium acetate anhydrous market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
    Global Sodium Acetate Trihydrate & Sodium Acetate Anhydrous Market, By Product Product type:
    Global Sodium Acetate Trihydrate & Sodium Acetate Anhydrous, By End-Use:

 Fresenius Kabi Issues Voluntary Recall of Sodium Acetate Injection, USP Due to the Presence of Particulate Matter

Retrieved on: 
Monday, March 7, 2022
FDA, Medical Devices, Health, Pharmaceutical, Medical Supplies, Infection, Patient, Heart, Hospital, Sodium acetate, Aluminium, Iron, Swelling, Death, USP, Sodium, Blood, Cellulose, Multimedia, Travel, Oxygen, Pharmacy, Stroke, Particulates, Brain, Silicon, Chromium, Carbon

Fresenius Kabi USA is voluntarily recalling seven lots of Sodium Acetate Injection, USP, 400 mEq/100 mL (4 mEq/mL), 100 mL fill in a 100 mL vial to the user level due to the presence of particulate matter found in reserve and/or stability sample vials.

Key Points: 
  • Fresenius Kabi USA is voluntarily recalling seven lots of Sodium Acetate Injection, USP, 400 mEq/100 mL (4 mEq/mL), 100 mL fill in a 100 mL vial to the user level due to the presence of particulate matter found in reserve and/or stability sample vials.
  • Microscopic and elemental analyses determined the presence of particulates composed of carbon and oxygen with varying amounts of iron and trace amounts of sodium, silicon, chromium, aluminum and cellulose.
  • View the full release here: https://www.businesswire.com/news/home/20220304005573/en/
    The administration of an injectable product that contains particulate matter may result in local irritation or swelling or infection in response to the foreign material.
  • Sodium Acetate Injection, USP is indicated as a source of sodium, for addition to large volume IV fluids to prevent or correct low blood sodium levels in patients with restricted or no oral intake.

Milla Pharmaceuticals Inc. Announces Approval of a Generic Version of Magnesium Sulfate in Water for Injection, in Non-PVC, Single-Patient Use Containers

Retrieved on: 
Tuesday, November 9, 2021
Health, Pharmaceutical, Seizure, Water, Convulsion, Magnesium sulfate, Injection, CEO, Food, Sodium acetate, Plasma protein binding, Multimedia, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Â, Regulation of tobacco by the U.S. Food and Drug Administration, Eclampsia, Paracetamol, Acquisition, Infant, Hospital, Company, ANDA, Pre-eclampsia, ASHP, Central nervous system, Patient, FDA, Pharmaceutical industry, Fine chemical, Generic drug, Health, Pharmaceutical

View the full release here: https://www.businesswire.com/news/home/20211109005804/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211109005804/en/
    Magnesium Sulfate Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively.
  • Magnesium Sulfate Injection is currently on the ASHP drug shortage list of essential medications.
  • This approval and near-term launch of Magnesium Sulfate Injection will help to reduce supply issues experienced in the US.
  • Magnesium Sulfate Injection is another example of a product in shortage in the US market for which we can offer a high-quality generic equivalent to the patients in need.

Milla Pharmaceuticals Announces Approval and Launch of a Generic Version of Sodium Acetate Injection 2MEQ/mL by Pfizer Inc.

Retrieved on: 
Thursday, August 26, 2021
Health, FDA, Infectious Diseases, Other Health, General Health, Pharmaceutical, Biotechnology, Novartis, Acquisition, Sodium, Food, Regulation of tobacco by the U.S. Food and Drug Administration, Acetate, Hospital, Multimedia, Medication, ANDA, Hyponatremia, Patient, Sodium acetate, CEO, Sale, FDA, CGT, Generic drug, Pharmaceutical industry, Fine chemical

Milla Pharmaceuticals, a subsidiary of the Alter Pharma Group , announced that it has received abbreviated new drug application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for its generic version of Sodium Acetate Injection 2MEQ/mL.

Key Points: 
  • Milla Pharmaceuticals, a subsidiary of the Alter Pharma Group , announced that it has received abbreviated new drug application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for its generic version of Sodium Acetate Injection 2MEQ/mL.
  • The FDA has recently listed Sodium Acetate Injection 2MEQ/mL on their FDA Drug Shortages List .
  • Woodward Pharma Services LLC is excited to partner with Milla Pharmaceuticals to offer Sodium Acetate as part of Woodwards growing hospital product portfolio, said Nirav Patel, President of Woodward Pharma Services LLC.
  • This achievement marks a milestone for Milla Pharmaceuticals and the Alter Pharma Group not only as their first ANDA approval but also as a first-cycle review approval and garnering FDAs coveted CGT Exclusivity.

Global Sodium Acetate Market 2018-2022

Retrieved on: 
Monday, June 18, 2018
Chemistry, Acetates, Desiccants, Reducing agents, Sodium acetate, Sodium

Based on its formation, sodium acetate occurs in two formsthe crystal form called sodium acetate trihydrate (SAT) and the anhydrous form called sodium acetate anhydrous (SAA).

Key Points: 
  • Based on its formation, sodium acetate occurs in two formsthe crystal form called sodium acetate trihydrate (SAT) and the anhydrous form called sodium acetate anhydrous (SAA).
  • Technavio's analysts forecast the global sodium acetate market to grow at a CAGR of 7.19% during the period 2018-2022.
  • The report covers the present scenario and the growth prospects of the global sodium acetate market for 2018-2022.
  • The market is divided into the following segments based on geography:
    Technavio's report, Global Sodium Acetate market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts.

Global Sodium Acetate Market 2018-2022: Growing Prominence in Medical and Pharmaceutical Sectors

Retrieved on: 
Friday, June 15, 2018
Chemistry, Acetates, Sodium acetate, Sodium, Benzoic acid, Citric acid, Potassium acetate

The global sodium acetate market to grow at a CAGR of 7.19% during the period 2018-2022.

Key Points: 
  • The global sodium acetate market to grow at a CAGR of 7.19% during the period 2018-2022.
  • Global Sodium Acetate market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts.
  • The end-use applications of sodium acetate such as water treatment, chemical agents, cosmetics, animal feeds, concrete sealing, and buffer solution for molecular biology are driving the global sodium acetate market.
  • The global sodium acetate market is facing a growing threat from other substitutes such as sodium citrate, sodium phosphate, malic acid, benzoic acid, sodium benzoate, and potassium acetate.